Market Newsdesk

PHILADELPHIA, Jan. 14, 2021 /PRNewswire/ — Rush Street Interactive, Inc. (“RSI”) (NYSE: RSI), today announced that a woman from Harrisburg, PA hit the Divine Fortune jackpot while playing on her mobile phone at PlaySugarHouse.com, one of RSI’s flagship brands. The winner, who wishes to remain anonymous, hit the jackpot with an 88-cent bet, winning $127,247.40. This is the second jackpot win of 2021 with a bet of one dollar or less on one of RSI’s online casinos in Pennsylvania, the first being on BetRivers.com.

“We love when our players win large jackpots, especially with small bets,” said Mattias Stetz, COO of RSI, which operates PlaySugarHouse.com.  “It shows that no matter the size of the bet, anyone can be a winner!”

This is the eighteenth Divine Fortune jackpot winner since its launch in 2019 on RSI’s two online casinos in Pennsylvania, BetRivers.com and PlaySugarHouse.com. 

About RSI

Founded in 2012 by gaming industry veterans, RSI is a market leader in online casino and sports betting in the U.S. The Company launched its first online gaming casino site, PlaySugarHouse.com in New Jersey, in September 2016 and was the first gaming company to launch a regulated online gaming site in Pennsylvania.  With its BetRivers.com sites, Rush Street Interactive was also the first to launch regulated online gaming in the states of Indiana, Colorado and, most recently, Illinois. Rush Street Interactive was named the 2020 Global Gaming Awards Digital Operator of the Year, and the 2020 EGR North America Awards Casino Operator of the Year and Customer Service Operator of the Year. RSI has been an early mover in Latin America and was the first U.S.-based gaming operator to launch a legal and regulated online casino and sportsbook, RushBet.co, in the country of Colombia. For more information, visit www.rushstreetinteractive.com.

 

View original content:http://www.prnewswire.com/news-releases/a-pa-woman-turns-cents-into-six-figures-with-a-divine-fortune-jackpot-hit-at-playsugarhousecom-301208254.html

SOURCE Rush Street Interactive

REDWOOD CITY, Calif., Jan. 14, 2021 /PRNewswire/ — AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced preliminary unaudited financial results and other information in connection with its participation in investor presentations, meetings and events during the week of the 39^th Annual J.P. Morgan Healthcare Conference. The Company will post its revised corporate presentation in the investor section of its website.

Key Highlights of 2020

• DSUVIA® achieved Milestone C approval from the Department of Defense (DoD), a decision that approves DSUVIA for use in all U.S. Army sets, kits and outfits (SKOs). Initial stocking orders have begun for U.S. Army SKOs and are expected to approximate $30 million over the next three years, dependent on troop deployment schedules.
• In March, AcelRx announced an agreement with Brigham and Women’s Hospital for an investigator-initiated study of DSUVIA led by Richard D. Urman MD, MBA, Associate Professor of Anesthesia and co-director of the Center for Perioperative Research at Brigham and Women’s Hospital and Harvard Medical School. This study is ongoing and is evaluating the perioperative use of DSUVIA in patients undergoing spine surgery compared to their standard intravenous (IV) opioid regimen.
• In July, AcelRx entered into a distribution agreement with Zimmer Biomet to market DSUVIA within the dental and oral surgery markets in the United States exclusively through Zimmer Biomet’s Dental division. The formal launch is planned in 2021, once Zimmer Biomet receives necessary licenses. The estimated applicable market in dental surgeries is over 7 million annual procedures.
• In August, AcelRx announced the publication of a study entitled, “Reduced Opioid Use and Reduced Time in the Postanesthesia Care Unit Following Preoperative Administration of Sublingual Sufentanil in an Ambulatory Surgery Setting,” by Christian Tvetenstrand, MD and Michael Wolff, MD, in the Journal of Clinical Anesthesia and Pain Management (Tvetenstrand and Wolff Study). Highlights of the publication included a greater than 50% overall reduction in opioids administered perioperatively and a 34% reduction in postanesthesia care unit (PACU) time in the DSUVIA-treated patients compared to historical controls. See Cautionary Statements section below.
• In August, AcelRx announced an investigator-initiated study with Cleveland Clinic evaluating the effects of DSUVIA on post-operative recovery from orthopedic surgery. This double-blind study is ongoing and compares DSUVIA to IV fentanyl for patients undergoing knee arthroscopy.
• In September, AcelRx announced that the U.S. military’s access to DSUVIA was expanded with the addition of DSUVIA to the DoD Joint Deployment Formulary.
• In September, the U.S. Army awarded AcelRx a contract of up to $3.6 million over four years for the purchase of DSUVIA to support a DoD study to aid the development of clinical practice guidelines.
• In December, AcelRx announced the publication of clinical data in an article in the Journal of Universal Surgery entitled, “A Medication Use Evaluation of Sufentanil Sublingual Tablet 30 mcg for the Perioperative Management of Surgical Pain,” by lead author Koth Cassavaugh, PharmD, Director of Pharmacy (the Cassavaugh Evaluation), which reported that perioperative dosing of DSUVIA can provide more rapid PACU recovery times compared to standard IV opioid administration. In addition, patients in the control group received 66% higher mean dosing of intraoperative IV opioids compared to patients receiving DSUVIA and postoperative opioid use for the DSUVIA group was less than half of the control IV opioid group, with orthopedic surgery patients having the largest decrease (69%). See Cautionary Statements section below.
• Achieved 348 formulary approvals through the close of 2020, a significant achievement in a year with COVID-related restrictions and delays.
• Preliminary unaudited FY 2020 revenues approximated $5.4 million.
• Preliminary December 31, 2020 cash, cash equivalents and short-term investments balance was $42.9 million.

“I’m pleased with our team’s commercial execution during these challenging times,” said Vince Angotti, AcelRx Chief Executive Officer.  “We expect further real-world data to support the value proposition of DSUVIA as an alternative to IV opioids, and we continue to make solid progress on the four pillars of our revenue plan.  I look forward to providing further updates during our year-end earnings call.”

The information above related to the Company’s expected operating results for the year ended and as of December 31, 2020, including revenue and cash, cash equivalents and short-term investments, is preliminary, has not been audited and is subject to change upon completion of the audit of the Company’s financial statements as of and for the year ended December 31, 2020.

About DSUVIA (sufentanil sublingual tablet), 30 mcg

DSUVIA®, known as DZUVEO™ in Europe, approved by the FDA in November 2018, is indicated for use in adults in certified medically supervised healthcare settings, such as hospitals, surgical centers, and emergency departments, for the management of acute pain severe enough to require an opioid analgesic, and for which alternative treatments are inadequate. DSUVIA was designed to provide rapid analgesia via a non-invasive route and to eliminate dosing errors associated with intravenous (IV) administration. DSUVIA is a single-strength solid dosage form administered sublingually via a single-dose applicator (SDA) by healthcare professionals. Sufentanil is an opioid analgesic previously only marketed for IV and epidural anesthesia and analgesia. The sufentanil pharmacokinetic profile when delivered sublingually avoids the high peak plasma levels and short duration of action observed with IV administration. The European Commission approved DZUVEO for marketing in Europe in June 2018 and the Company is currently in discussions with potential European marketing partners. This release is intended for investors only. For more information, including important safety information and black box warning for DSUVIA, please visit www.DSUVIA.com.

About AcelRx Pharmaceuticals, Inc.

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings.  AcelRx’s proprietary, non-invasive sublingual formulation technology delivers sufentanil with consistent pharmacokinetic profiles. AcelRx has one approved product in the U.S., DSUVIA^® (sufentanil sublingual tablet, 30 mcg), known as DZUVEO™ in Europe, indicated for the management of acute pain severe enough to require an opioid analgesic for adult patients in certified medically supervised healthcare settings, and one product candidate, Zalviso^® (sufentanil sublingual tablet system, SST system, 15 mcg), an investigational product in the U.S., is being developed as an innovatively designed patient-controlled analgesia (PCA) system for reduction of moderate-to-severe acute pain in medically supervised settings. DZUVEO and Zalviso are both approved products in Europe.  For additional information about AcelRx, please visit www.acelrx.com.

Cautionary Statements

Tvetenstrand and Wolff Study
The study compared a prospective group of patients with preoperative dosing of a single sublingual DSUVIA tablet to a historical control group receiving standard intravenous (IV) opioid administration for same-day general surgery procedures. A total of 127 patients were evaluated in the study. Study limitations include that it was an open-label study, the retrospective nature of the control group, and the focus on only general surgery patients. AcelRx did not provide funding for the conduct of the Tvetenstrand and Wolff Study but did fund medical writing support. Dr. Tvetenstrand is a paid consultant of AcelRx.

Cassavaugh Evaluation
The evaluation focused on 140 patients who were dosed with DSUVIA compared to 158 patients who had been dosed with traditional IV opioids during the same time period undergoing the same surgical procedures. Study limitations included that it was a single-center, retrospective study of DSUVIA dosing in a surgical patient population and both inpatient and outpatient surgery data was combined. The study did not control for whether patients were opiate naïve or opiate tolerant in the treatment groups, however, there is no reason for these patients to be present at a substantially higher frequency in either group. AcelRx did not provide funding for the conduct of the evaluation but did fund medical writing support. Dr. Cassavaugh is a paid consultant of AcelRx.

Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements related to revenues and cash, cash equivalents and short-term investments AcelRx expects to report for fiscal year 2020, the timing of the procurement of DSUVIA by the military, the timing of the formal launch by Zimmer Biomet, and expectations for further real-world data to support the value proposition of DSUVIA as an alternative to IV opioids. These and any other forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking terminology such as “believes,” “expects,” “anticipates,” “may,” “will,” “should,” “seeks,” “approximately,” “intends,” “plans,” “estimates,” or the negative of these words or other comparable terminology. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied by such statements. In addition,  such risks and uncertainties may include, but are not limited to, those described in AcelRx’s annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the Securities and Exchange Commission (SEC). You are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date such statements were first made. Except to the extent required by law, AcelRx undertakes no obligation to publicly release the result of any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events.

 

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/acelrx-announces-year-end-2020-metrics-and-review-of-2020-achievements-301208257.html

SOURCE AcelRx Pharmaceuticals, Inc.

NEW YORK, Jan. 14, 2021 /PRNewswire/ — The Neuberger Berman Large Cap Value Fund Institutional Class (ticker: NBPIX) (the “Fund”) generated a 14.67% return for the 2020 calendar year, ranking in the fourth percentile of Morningstar, Inc.’s Large Value Category (out of 1,200 large value funds), and outperforming the Russell 1000 Value Index return of 2.80% by 1,187 basis points. The Fund’s returns were 12.19% for the three years, 15.56% for five years, and 10.68% for 10 years ended December 31, 2020 placing it in the 1^st (out of 1,128 large value funds), 1^st (out of 998 large value funds), and 26^th (out of 716 large value funds) Morningstar, Inc. percentiles respectively. The Fund’s Institutional Class generated a 28.66% return for the fourth quarter of 2020, ranking in the second percentile of Morningstar, Inc.’s Large Value Category (out of 1,215 large value funds).

The Fund’s Institutional Class is rated 4-stars by Morningstar, Inc. for the year ended December 31, 2020 (out of 1,128 large value funds) and for the 3-, 5- and 10-year periods ended December 31, 2020 it is rated 5 stars (out of 1,128 large value funds), 5 stars (out of 998 large value funds) and 3 stars (out of 716 large value funds), respectively.

For the past 13 years, growth has mostly outperformed value investing. An acceleration the past few years leaves many investors overweight growth relative to value in their portfolios. In addition to growth funds owning large positions in the FAANG stocks, many value funds, chasing returns, now own these same stocks in their top ten holdings.

Neuberger Berman Large Cap Value portfolio manager Eli Salzmann believes this is a mistake arguing that value is on the cusp of a 3- to 5-year run of outperformance relative to growth, due to close some of the performance gap of the past few years. Record amounts of monetary and fiscal stimulus—along with deglobalization–is a recipe for higher inflation and interest rates that will dramatically favor value over growth. Salzmann has a strong view of better GDP than investors generally believe, expecting GDP to be in excess of 7% for 2021. In this environment, investors should be mindful of what they own and the exposures that truly exist in their holdings.

For his Fund, Salzmann utilizes an active value-investing discipline with a patient, conviction-based approach creating a portfolio with high active share, currently greater than 80% and consistent value exposure. He is joined by David Levine in managing equities for Large Cap Value strategies at Neuberger Berman.

Salzmann’s team conducts independent, “bottom-up” fundamental and quantitative research to identify nuances of each company that cannot be captured solely by financial characteristics.

December 2020 marked nine years since Mr. Salzmann has managed the fund. Mr. Salzmann has over 30 years of investing experience. The Large Cap Value team seeks to mitigate the downside and avoid “value traps” through their disciplined focus on rational valuations and catalysts.

About Neuberger Berman

Neuberger Berman, founded in 1939, is a private, independent, employee-owned investment manager. The firm manages a range of strategies—including equity, fixed income, quantitative and multi-asset class, private equity, real estate and hedge funds—on behalf of institutions, advisors and individual investors globally. With offices in 24 countries, Neuberger Berman’s diverse team has over 2,300 professionals. For six consecutive years, the company has been named first or second in Pensions & Investments Best Places to Work in Money Management survey (among those with 1,000 employees or more). In 2020, the PRI named Neuberger Berman a Leader, a designation awarded to fewer than 1% of investment firms for excellence in Environmental, Social and Governance (ESG) practices. The PRI also awarded Neuberger Berman an A+ in every eligible category for our approach to ESG integration across asset classes. The firm manages $405 billion in client assets as of December 31, 2020. For more information, please visit our website at www.nb.com.

Media Contact: Alex Samuelson, 212 476 5392, [email protected]  

An investor should consider the Fund’s investment objectives, risks and fees and expenses carefully before investing. This and other important information can be found in the Fund’s prospectus or summary prospectus, which you can obtain by calling 877.628.2583. Please read the prospectus or summary prospectus carefully before making an investment
.

The Neuberger Berman Large Cap Value Fund – Institutional Class is rated 4-stars by Morningstar, Inc. for the year ended December 31, 2020 (out of 1,128 large value funds) and for the 3-, 5- and 10-year periods ended December 31, 2020 it is rated 5 stars (out of 1,128 large value funds), 5 stars (out of 998 large value funds) and 3 stars (out of 716 large value funds), respectively.

P
lease 

click here

 for a summary of the Neuberger Berman Large Cap Value Fund’s investment risks in addition to other important disclosures.

The Russell 1000® Value Index measures the performance of those Russell 1,000 companies with lower price-to-book ratios and lower forecasted growth values. Please note that indices do not take into account any fees and expenses of investing in the individual securities that they track, and that individuals cannot invest directly in any index. Data about the performance of these indices are prepared or obtained by the Manager and include reinvestment of all dividends and capital gain distributions.

For each retail mutual fund with at least a three-year history, Morningstar calculates a Morningstar Rating based on a Morningstar Risk-Adjusted Return measure that accounts for variation in a fund’s monthly performance (including the effects of sales charges, loads, and redemption fees), placing more emphasis on downward variations and rewarding consistent performance. The top 10% of funds in each category receive five stars, the next 22.5% receive four stars, the next 35% receive three stars, the next 22.5% receive two stars and the bottom 10% receive one star. (Each share class is counted as a fraction of one fund within this scale and rated separately, which may cause slight variations in the distribution percentages.) The Overall Morningstar Rating for a retail mutual fund is derived from a weighted average of the performance figures associated with its three-, five- and 10-year (if applicable) Morningstar Rating metrics. Ratings are ©2021 Morningstar, Inc. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

Morningstar rankings are based on Morningstar total returns, which include both income and capital gains or losses and are not adjusted for sales charges or redemption fees, to all funds that have the same Morningstar category. The highest percentile rank is 1 and the lowest is 100.  As of December 31, 2020 the Fund’s Institutional Class shares rank in the top 2^nd percentile for the fourth quarter of 2020 (of 1,215 funds), in the top 4^th percentile for one year (of 1,200 funds), top 1^st percentile over three and five years (of 1,128 and 998 large value funds, respectively), and top 26^th percentile for ten years (out of 716 large value funds). As of December 31, 2020, the Fund’s Class A shares rank in the top 2^nd percentile for the fourth quarter of 2020 (of 1,215 funds), in the top 4^th percentile for one year (of 1,200 funds), top 2^nd percentile over three and five years (of 1,128 and 998 large value funds, respectively), and top 40^th percentile for ten years (of 716 large value funds). Rankings are ©2021 Morningstar, Inc. All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers, (2) may not be copied or distributed and (3) is not warranted to be accurate, complete or timely.

Morningstar Large Value category

Large-value portfolios invest primarily in big U.S. companies that are less expensive or growing more slowly than other large-cap stocks. Stocks in the top 70% of the capitalization of the U.S. equity market are defined as large cap. Value is defined based on low valuations (low price ratios and high dividend yields) and slow growth (low growth rates for earnings, sales, book value, and cash flow).

NEUBERGER BERMAN LARGE CAP VALUE FUND RETURNS (%)

Performance data quoted represent past performance, which is no guarantee of future results. The investment return and principal value of an investment will fluctuate so that an investor’s shares, when redeemed, may be worth more or less than their original cost. Results are shown on a “total return” basis and include reinvestment of all dividends and capital gains distributions. Current performance may be higher or lower than the performance given. For current performance data, including current to the most recent month end, please visit www.nb.com/performance
.

Average annual total returns with sales charge reflect deduction of current maximum initial sales charge of 5.75% for Class A shares and applicable contingent deferred sales charges (CDSC) for Class C shares. The maximum CDSC for Class C shares is 1%, which is reduced to 0% after 1 year.

Gross expense represents the total annual operating expenses that shareholders pay (after the effect of fee waivers and/or expense reimbursement). The Fund’s investment manager has contractually undertaken to waive and/or reimburse certain fees and expenses of the Fund so that the total annual operating expenses are capped (excluding interest, taxes, brokerage commissions, acquired fund fees and expenses, dividend and interest expenses relating to short sales, and extraordinary expenses, if any; consequently, total (net) expenses may exceed the contractual cap) through 8/31/24 for Institutional Class at 0.70%, 1.11% for Class A, 1.86% for Class C, 1.36% for Class R3, 0.60% for Class R6, 1.50% for Trust Class, for Advisor class at 1.50% (each as a % of average net assets). As of the Fund’s most recent prospectuses, the Manager was not required to waive or reimburse any expenses pursuant to this arrangement. Absent such arrangements, which cannot be changed without Board approval, the returns may have been lower. Information as of the most recent prospectuses dated December 15, 2020.

Neuberger Berman Large Cap Value Fund – Top 10 Holdings (%) as of November 30, 2020

All information is as of December 31, 2020 unless otherwise indicated and is subject to change without notice. Firm data, including employee and assets under management figures, reflects collective data for the various affiliated investment advisers that are subsidiaries of Neuberger Berman Group LLC. Firm history/timeline includes the history of all firm subsidiaries, including predecessor entities and acquisitions. 

The “Neuberger Berman” name and logo and “Neuberger Berman Investment Advisers LLC” name are registered service marks of Neuberger Berman Group LLC. The individual fund names in this piece are either service marks or registered service marks of Neuberger Berman Investment Advisers LLC, an affiliate of Neuberger Berman BD LLC, distributor, member FINRA.

The “Neuberger Berman” name and logo are registered service marks of Neuberger Berman Group LLC.

© 2021 Neuberger Berman Group LLC. All rights reserved.

View original content to download multimedia:http://www.prnewswire.com/news-releases/is-it-time-for-value-neuberger-berman-top-ranked-value-manager-says-it-is-as-fund-achieves-top-1-rank-for-3-and-5-years-301208476.html

SOURCE Neuberger Berman

Ft Lauderdale, Fla., Jan. 14, 2021 /PRNewswire/ — NxGen Brands Inc. (OTC:NXGB) (“NXGB” or the “Company”), announced today that the response to its most recent press release regarding their cannabis dispensary delivery services platform app was overwhelming in both its speed and scope. The Company received calls from across the nation from a wide range of dispensaries – some small mom & pops and some with dispensaries throughout many jurisdictions – all wanting to know more about the technology and how it can be implemented into their operations. 

On January 12^th, the company previously announced that it has partnered with a nationally recognized digital supply chain & blockchain developer, Bengala Technologies, to allow the Company to enter into the rapidly growing U.S. cannabis dispensary delivery services market. The press release revealed that, its partnership will allow the company to deliver is own proprietary brands of THC and Leafywell products and will allow it to create a national network to provide delivery services for dispensaries across the country. Here is a video news release explaining it – https://youtu.be/Buu0Hch0mJo

Angel Burgos, the Company CEO said: “Very early this morning the phones started ringing and didn’t stop all day. Cannabis companies of all sizes that provide or want to provide delivery services, were excited to find a solution to allow them to either enter the delivery market or to ramp-up their existing delivery sales and revenues. “When will it be available?” was the most answered question and most were extremely satisfied when we said that the launch will be as planned for Q2 2021. This incredible response reinforces management’s position that becoming a third-party service/technology partner/supplier, should significantly increase the Company’s revenue through licensing of the product while tremendously benefitting our shareholder base.”

Burgos also said that “NxGen Brands will be announcing a new brand name for the platform to go along with its launch in the Q1 2021”.

About
Bengala Technologies:

Bengala Technologies LLC, achieved excellence in the field of blockchain consulting and development by creating and deploying custom decentralized blockchain and supply apps including Supply Chain, Blockchain and Smart Contract Development applications.

For more information on Bengala Technologies LLC go to: https://bengalatech.io

About NxGen Brands, Inc:

NxGen Brands, Inc. is a diversified portfolio company compromising business lines directed at serving consumer products demands in a variety of markets and across a broad spectrum of industries. NxGen Brands, Inc. maneuvers its proprietary companies through critical stages of market development, including conceptualization, go-to-market strategies, engineering, product integration and distribution efficiency protocols. NxGen Brands, Inc. is partnered with a well-known software development and consulting company, Bengala Technologies LLC, which is developing significant enhancements in the supply chain management space. In collaboration with our partners, we seek to provide an infrastructure that meet anticipated marketplace needs on both large and small scale volume levels. One of our principal aims is our pursuit to leverage equity, acquire, merge and or joint venture with early-stage companies in emerging industries, to stimulate growth, cash flow , and increase broader distribution channels. 

NxGen Brands, Inc created and owns a subsidiary, NxGen Brands LLC dba: Leafywell™. Our websites can be viewed at www.leafywell.com and www.nxgenbrands.com.

For more information on “NXGB” the corporation, please visit the corporate website at https://www.nxgenbrands.com.

To be added to the Company investor email list, please email [email protected] with “NXGB” in the subject line.

FORWARD-LOOKING STATEMENTS:

This press release contains forward-looking statements as defined within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements relate to future events, including our ability to raise capital, or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

For a discussion of these risks and uncertainties, please see our filings with the OTC Markets Group Inc. Our public filings with the OTC Markets Group Inc are available from commercial document retrieval services and at the website maintained by the OTC Markets at: https://otcmarkets.com/stock/NXGB/disclosure

Contact:

[email protected]

Phone: (888) 315-6339

 

View original content:http://www.prnewswire.com/news-releases/nxgen-brands-inc-cannabis-dispensary-delivery-services-platform-app-excitement-builds-301208132.html

SOURCE NxGen Brands Inc.

NEW YORK, Jan. 14, 2021 /PRNewswire/ — Direxion announced today the recent launch of the Direxion World Without Waste ETF (Ticker: WWOW). WWOW invests in 50 companies at the forefront of the move to a circular economy from a linear one. Until recently, the ‘take-make-consume-waste’ of resources within a linear economy has prevailed. Raw material transformed into a product, and after its utility was over, its lifecycle ended and it became waste. Alternatively, the regenerative framework provided by a circular economy affords companies the ability to address environmental and sustainability priorities, drive innovation, and push for competitiveness, while generating growth.

“Investors have embraced ETFs with exposure to renewable and alternative sources of energy, but a circular economy encapsulates a far broader range of companies,” said David Mazza, Managing Director at Direxion. “WWOW is the first US-listed fund providing direct exposure to companies helping to make a world without waste.”

WWOW seeks investment results, before fees and expenses, which track the Indxx US Circular Economy Index. The Indxx US Circular Economy Index tracks the performance of 50 US-listed companies that are representative of the transformative shift from the linear model of economy to a circular one. The index includes five sub-themes central to the circular economy, providing investors access to the shifting paradigm in growing segments such as biofuels, solar power, and waste management, along with collaboration and content sharing platforms. The top 10 companies from each sub-theme, by largest total market capitalization, will form the final index.

The five sub-themes are:

Sustainability of Resources: Provide renewable energy – bio-based or fully recyclable input material – to replace single-lifecycle inputs.

Resource Recovery: Recover useful resources and energy from disposed products or byproducts.

Life Cycle Extension: Extend the working lifecycle of products and components by repairing, upgrading and reselling.

Sharing Platforms: Enable the increased utilization rate of products through shared access, ownership and use.

Product as a Service: Offer product access, and retain ownership, to internalize the benefits of circular resource productivity.

The top holdings in the Indxx US Circular Economy Index represent large, mid, and small cap firms across a mix of unique sub-industries representative of a world without waste. Many of the holdings focus on the Information Technology sector, with further exposure to the Communication Services, Consumer Discretionary and Industrials sectors.

About Direxion:

Direxion equips investors who are driven by conviction with ETF solutions built for purpose and fine-tuned for precision. These solutions are available for a broad spectrum of investors, whether executing short-term tactical trades, investing in macro themes, or building long-term asset allocation strategies. Direxion’s reputation is founded on developing products that precisely express market perspectives and allow investors to manage their risk exposure. Founded in 1997, the company has approximately $19.7 billion in assets under management as of December 31, 2020. For more information, please visit www.direxion.com.

For more information on all Direxion Shares daily leveraged ETFs, go to


direxion.com


, or call us at 866.476.7523.

An investor should carefully consider a Fund’s investment objective, risks, charges, and expenses before investing. A Fund’s prospectus and summary prospectus contain this and other information about the Direxion Shares. To obtain a Fund’s prospectus and summary prospectus call 866-716-0735 or visit our website at direxion.com. A Fund’s prospectus and summary prospectus should be read carefully before investing

.

Direxion Shares Risks – Investing involves risk including possible loss of principal. There is no guarantee the investment strategy will be successful. The value of stocks of information technology companies and companies that rely heavily on innovation and technology are particularly vulnerable to rapid changes in technology product cycles, rapid product obsolescence, government regulation and competition, both domestically and internationally, including competition from competitors with lower production costs. Innovative technology companies may struggle to capitalize on new technology or may face competition and obsolescence. Additional risks of the Fund include, but are not limited to, Index Correlation/Tracking Risk, Index Strategy Risk, Market Disruption Risk, and risks associated with the market capitalizations of the securities in which the Fund may invest.  Please see the summary and full prospectuses for a more complete description of these and other risks of the Fund.

Distributor: Foreside Fund Services, LLC.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/direxion-launches-world-without-waste-etf-301208267.html

SOURCE Direxion